A blood test initially developed to detect Alzheimer’s disease may hold a key to diagnosing a range of other, less common but often devastating conditions known as amyloidoses. Researchers have discovered that elevated levels of phosphorylated tau—a protein that accumulates in the brains of Alzheimer’s patients—likewise appear in the blood of individuals with certain types of amyloidosis, offering a potential new avenue for earlier and more accurate diagnosis. This discovery, published in Nature Medicine, could significantly improve the lives of people living with these challenging diseases.
Amyloidoses aren’t a single disease, but rather a group of disorders caused by the buildup of abnormal proteins, called amyloid, in organs and tissues. These deposits can disrupt normal function, leading to a variety of symptoms depending on which organs are affected. There are several types, including immunoglobulin light chain (AL) amyloidosis and transthyretin (ATTR) amyloidosis, both of which can cause significant organ damage. Currently, diagnosis often relies on tissue biopsies, which can be invasive and sometimes tough to obtain. A readily accessible blood test for amyloidosis has long been a goal for clinicians.
The study, led by researchers at the University Hospital Zurich, focused on two main types of amyloidosis: AL amyloidosis, often affecting the heart and kidneys, and ATTR amyloidosis, which can impact the heart, nerves, and other tissues. They analyzed blood samples from hundreds of patients with these conditions, as well as healthy controls and individuals with Alzheimer’s disease. The findings revealed consistently elevated levels of phosphorylated tau in the blood of patients with both AL and ATTR amyloidosis. The levels weren’t as high as those typically seen in Alzheimer’s, but were significantly above those found in healthy individuals.
How Phosphorylated Tau Became a Potential Biomarker for Multiple Diseases
Phosphorylated tau has been a focal point in Alzheimer’s research for decades. In Alzheimer’s, this protein forms tangles inside brain cells, contributing to neuronal dysfunction and cognitive decline. The development of highly sensitive assays to measure phosphorylated tau in cerebrospinal fluid and, more recently, in blood, has revolutionized Alzheimer’s diagnostics. Researchers have been working to refine these blood tests to improve their accuracy and accessibility. The Alzheimer’s Association provides detailed information on diagnostic tests.
The surprising link to amyloidosis emerged as researchers noticed similarities in the protein misfolding processes underlying both Alzheimer’s and certain types of amyloidosis. Both involve proteins changing shape and aggregating, ultimately leading to cellular damage. Dr. Simon A. Kaeser, the senior author of the study, explained that the team initially investigated whether the tau elevation in amyloidosis was simply a consequence of co-existing Alzheimer’s pathology. However, they found elevated levels even in patients with no evidence of Alzheimer’s, suggesting a more direct connection.
Implications for Diagnosis and Treatment
The potential benefits of a blood-based biomarker for amyloidosis are substantial. Currently, diagnosing these conditions often requires a biopsy of affected tissue—for example, the heart or kidney—which carries inherent risks. A blood test could provide a less invasive and more readily available screening tool, allowing for earlier detection and intervention. Early diagnosis is crucial, as treatments for amyloidosis are most effective when initiated before significant organ damage occurs.
“If we can identify patients earlier, we can start treatment sooner and potentially prevent irreversible organ damage,” says Dr. Kaeser. Current treatments for AL amyloidosis involve chemotherapy to reduce the production of abnormal antibodies, while treatments for ATTR amyloidosis include medications that stabilize the transthyretin protein. The availability of a reliable biomarker could also accelerate the development of new therapies by providing a way to monitor treatment response.
Challenges and Future Research
While the findings are promising, researchers caution that the phosphorylated tau blood test is not yet ready for widespread clinical use. Further studies are needed to validate the results in larger and more diverse populations. It’s also key to determine the optimal cutoff levels for diagnosing amyloidosis and to assess how the test performs in individuals with other conditions that might affect tau levels.
One key area of ongoing research is understanding why phosphorylated tau is elevated in amyloidosis. Is it a direct consequence of amyloid deposition, or does it play a more active role in the disease process? Answering this question could lead to new therapeutic targets. Researchers are also exploring whether the test can be used to monitor disease progression and predict which patients are most likely to respond to treatment.
The team is currently working on refining the assay and developing standardized protocols for its use. They hope to collaborate with other research centers to conduct larger clinical trials and ultimately bring this potentially life-changing test to patients. The development of this biomarker represents a significant step forward in the fight against amyloidosis, offering hope for earlier diagnosis, more effective treatment, and improved outcomes for those affected by these debilitating diseases.
Disclaimer: This article provides information for general knowledge and informational purposes only, and does not constitute medical advice. We see essential to consult with a qualified healthcare professional for any health concerns or before making any decisions related to your health or treatment.
Stay informed about the latest developments in amyloidosis research and diagnostics. Share this article with anyone who might benefit from this information.
